Ovid Therapeutics Inc. Quarterly Operating Income (Loss) in USD from Q2 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Ovid Therapeutics Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2016 to Q3 2024.
  • Ovid Therapeutics Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$13.2M, a 9.95% decline year-over-year.
  • Ovid Therapeutics Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$69.3M, a 30.2% decline year-over-year.
  • Ovid Therapeutics Inc. annual Operating Income (Loss) for 2023 was -$59.3M, a 6.72% decline from 2022.
  • Ovid Therapeutics Inc. annual Operating Income (Loss) for 2022 was -$55.5M, a 145% decline from 2021.
  • Ovid Therapeutics Inc. annual Operating Income (Loss) for 2021 was $124M.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$69.3M -$13.2M -$1.2M -9.95% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$68.2M -$20.5M -$6.35M -44.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$61.8M -$17.4M -$2.53M -17% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$59.3M -$18.2M -$6.02M -49.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-08
Q3 2023 -$53.3M -$12M +$775K +6.05% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$54M -$14.2M +$132K +0.93% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$54.2M -$14.9M +$1.38M +8.45% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$55.5M -$12.2M +$14.2M +53.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-08
Q3 2022 -$69.7M -$12.8M -$1.12M -9.61% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 -$68.6M -$14.3M +$8.54K +0.06% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-04
Q1 2022 -$68.6M -$16.3M -$193M -109% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-05
Q4 2021 $124M -$26.4M -$4.76M -22.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-13
Q3 2021 $129M -$11.7M +$4.72M +28.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $124M -$14.3M +$8.83M +38.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $115M $177M +$197M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$81.4M -$21.6M -$4.32M -25% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-15
Q3 2020 -$77.1M -$16.4M +$362K +2.16% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$77.5M -$23.1M -$9.82M -73.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$67.7M -$20.3M -$6.24M -44.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$61.4M -$17.3M -$4.15M -31.7% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-15
Q3 2019 -$57.3M -$16.8M -$3.59M -27.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 -$53.7M -$13.3M -$113K -0.85% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 -$53.6M -$14.1M -$624K -4.64% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$52.9M -$13.1M -$2.07M -18.7% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-11
Q3 2018 -$50.9M -$13.2M -$3.77M -40% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 -$47.1M -$13.2M -$2.92M -28.4% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$44.2M -$13.4M +$20.8M +60.8% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 -$65M -$11M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-07
Q3 2017 -$9.41M -$3.59M -61.8% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 -$10.3M -$4.87M -89.9% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 -$34.3M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q3 2016 -$5.81M Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 -$5.42M Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.